Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

Fig. 1

10H1 is a highly specific antibody against CREB3L1. On day 0, Huh7 cells stably transfected with a control shRNA or that targeting CREB3L1 were seeded at 4×105 cells per 60 mm dish. On day 1, cells were harvest, and cell lysates were subjected to immunoblot analysis with antibodies reacting against CREB3L1 (10H1 or Proteintech Cat# 11235-2-AP) and Actin

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us